NCT05493267RecruitingPhase 4
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Source: ClinicalTrials.gov · Last updated 10 Aug 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 3 Aug 2022
- Start date
- 3 Aug 2022
- Primary completion date
- 3 Aug 2025
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- NCT number
- NCT05493267
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From 3 Aug 2022 to the primary completion date, 3 Aug 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
Other
- Test confirms poor response to ZOL and IL-2 stimulation.
Who the study is looking for
- RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
- Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanghai Pulmonary Hospital, Shanghai. China Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.